Oncolytics Biotech (ONCY) Notes Payables (2019 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Notes Payables of $77000.0 for Q4 2025, down 89.02% year-over-year from $701532.2 in Q4 2024, and up 265.41% quarter-over-quarter from $21072.4 in Q3 2025.
Oncolytics Biotech (ONCY) Notes Payables (2019 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Notes Payables for 7 consecutive years, with $77000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables fell 89.02% year-over-year to $77000.0; the TTM figure through Dec 2025 stood at $77000.0 (down 89.02% YoY), while the FY2025 annual figure was $77000.0, down 66.52% from the prior year.
- Notes Payables climbed to $77000.0 in Q4 2025 per ONCY's latest filing, from $21072.4 in the prior quarter.
- Across five years, Notes Payables topped out at $3.9 million in Q3 2023 and bottomed at $21072.4 in Q3 2025.
- Historically, Notes Payables has averaged $453101.1 across 5 years, with a median of $119579.2 in 2021.
- Annual changes were most pronounced in 2023 — Notes Payables soared 10007.7% — and 2025, when it plunged 97.37%.
- Oncolytics Biotech's Notes Payables stood at $44426.8 in 2021, then surged by 31.0% to $58199.5 in 2022, then soared by 152.42% to $146907.1 in 2023, then jumped by 377.53% to $701532.2 in 2024, then plunged by 89.02% to $77000.0 in 2025.
- Business Quant data shows ONCY's Notes Payables at $77000.0 in Q4 2025, $21072.4 in Q3 2025, and $739033.6 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - |
| 10 | Oncolytics Biotech | 96.99 Mn | 96.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77,000.00 |
| Sep 30, 2025 | 21,072.42 |
| Jun 30, 2025 | 739,033.60 |
| Mar 31, 2025 | 850,238.10 |
| Dec 31, 2024 | 701,532.16 |
| Sep 30, 2024 | 800,494.32 |
| Jun 30, 2024 | 620,007.18 |
| Mar 31, 2024 | 462,336.53 |
| Dec 31, 2023 | 146,907.11 |
| Sep 30, 2023 | 3.88 Mn |
| Jun 30, 2023 | 113,901.23 |
| Mar 31, 2023 | 35,505.43 |
| Dec 31, 2022 | 58,199.53 |
| Sep 30, 2022 | 38,360.31 |
| Jun 30, 2022 | 24,593.79 |
| Mar 31, 2022 | 53,866.70 |
| Dec 31, 2021 | 44,426.82 |
| Sep 30, 2021 | 84,257.43 |
| Jun 30, 2021 | 125,257.15 |
| Mar 31, 2021 | 187,684.89 |